Fig. 1From: Limited efficacy of tocilizumab in adult patients with secondary hemophagocytic lymphohistiocytosis: a retrospective cohort studyTreatment response at D14, D28, and D56 was assessed as complete response (CR), partial response (PR), stable disease (SD), progressive disease (PD), or death in the two groupsBack to article page